Opthea Ltd at SRAX Sequire Biotechnology Conference (Virtual) Transcript
Hello, everyone, and thank you very much for this opportunity to participate in the Sequire Biotechnology Conference. It's a pleasure today to be here to take you through Opthea's program for the treatment of wet Age-Related Macular Degeneration.
We have a Phase-3 assay that's currently in clinical development. We're actively recruiting patients into two Phase-3 clinical trials where we are looking to read out the top line data from those Phase-3 studies in the second half of 2024. So very exciting assay. I think it really has the potential to change the treatment paradigm for a very large market, which is the wet-AMD market, for which there is currently only limited treatment available for patients.
So a little bit about Opthea Limited. We are a two-listed company. We were actually founded in 1984, listed on the Australian Stock Exchange. And we really become focused on ophthalmology in 2014 when we started developing OPT-302, which is a novel VEGF-C/D trap inhibitor for the treatment of the leading cause of blindness in people over the age
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
